DDX3 Inhibitor (Antiviral)

About Lead Discovery Siena

Lead Discovery Siena is a private, preclinical-stage biotechnology company founded in 2015 (originating from a 2012 spin-off). It leverages a multi-faceted platform combining AI/machine learning, medicinal chemistry, and biological services to advance its own drug candidates and service client programs. The company's strategy is built on fostering local and international collaborations, with a pipeline featuring promising assets in glioblastoma and broad-spectrum antivirals, alongside a proprietary Antibody Drug Conjugate (ADC) linker technology.

Therapeutic Areas

Other Broad-spectrum antiviral Drugs